📃 Paper Title: Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (Rezum II)
🧍 Author: Kevin McVary
🕒 Year: 2016
📚 Journal: The Journal of Urology
🌎 Country: Southern Illinois University, Springfield, Illinois
ㅤContext to the study:
What are the reported advantages of Rezum as a treatment for benign prostatic obstruction?
ㅤ✅ Take-home message of study:
In this US multicentre randomised sham-controlled trial, Rezum produced a rapid and durable improvement in male LUTS whilst preserving erectile and ejaculatory function and without serious adverse events. The majority needed a catheter post-operatively for an average of 3 days.
ㅤ US multicentre randomised sham-controlled trial.
ㅤ
Study participants:
197 men with IPSS >=13, Qmax <=15 mL/s, and prostate volume 3-80mL were randomised 2:1 to Rezum (n=136) or sham (61). Sham was rigid cystoscopy with simulated active treatment sounds.
ㅤ
ㅤ
Key study outcomes:
Reduction in IPSS was significantly greater following Rezum than sham (11.2, 50%, vs 4.3, 20%; p<0.0001). Qmax significantly improved by 6.2 mL/s at 3 months and was sustained to 12 months. Quality of life and BHPII were also significantly improved to 12 months. There was no new erectile dysfunction or serious adverse events. 90% of the Rezum group were catheterised for a mean of 3.4 days, of which 68% were catheterised based on surgical discretion, and 32% due to a failed TWOC prior to discharge.
ㅤ
ㅤ
Study Limitations:
The questionnaire related to patients resuming normal activity was administered at 3 months prior to unblinding, and there therefore may be some recall bias here.
ㅤ